← Back to Search

Stretching and toning exercise for Multiple Sclerosis

N/A
Waitlist Available
Led By Charles H Bombardier, PhD
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the cowat will be administered at six months after baseline.
Awards & highlights
No Placebo-Only Group

Summary

Cognitive impairment affects roughly 50% of people with multiple sclerosis (MS). There are currently no satisfactory medical treatments for cognitive impairments related to MS and alternative forms of treatment are needed. Exercise training can improve cognition in older adults and people with mild cognitive impairments, including those with early Alzheimer's disease. Therefore, the investigators plan to conduct the first definitive study that will test the theory that moderately intense aerobic exercise can improve cognition in people with MS-related impairment - specifically in information processing speed - more so than non-aerobic stretching and toning (both forms of exercise will be performed 3 days per week for 6 months). Primary study hypothesis: The investigators hypothesize greater improvement in speed of information processing from pre- to post-treatment in the aerobic exercise group compared to the stretching and toning group (attention control). Secondary study hypothesis: The investigators hypothesize greater improvement in other cognitive domains and patient reported outcomes from pre- to post-testing in the aerobic exercise group compared to the stretching and toning group (attention control). The investigators plan to recruit 125 adults with MS who can walk without assistance and without rest for at least 100 meters and have mild weaknesses in information processing speed. The investigators will randomly assign 50% of participants to an aerobic exercise program and 50% to a non-aerobic exercise program (stretching and toning). In order to determine whether the intervention is successful, the investigators will compare cognitive functioning in both exercise groups before the exercise-training program, at the end of the 6-month training program and three months after the end of the training program. If our study findings support our hypotheses, this would be a relatively no-barriers treatment option to further explore for other people with MS including people with greater and lesser baseline disability.

Eligible Conditions
  • Multiple Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and six months after baseline.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and six months after baseline. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Composite score of the Paced Auditory Serial Addition Test-3 (PASAT-3") and the oral version of the Symbol-Digit Modalities Test (SDMT)
Secondary study objectives
Brief Visuospatial Memory Test Revised (BVMTR)
California Verbal Learning Test, second edition (CVLT2)
Delis Kaplan Executive Function System Sorting Test (DKEFS)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Stretching and toning exerciseExperimental Treatment1 Intervention
Group II: Aerobic exerciseActive Control1 Intervention

Find a Location

Who is running the clinical trial?

National Multiple Sclerosis SocietyOTHER
97 Previous Clinical Trials
9,547 Total Patients Enrolled
95 Trials studying Multiple Sclerosis
9,193 Patients Enrolled for Multiple Sclerosis
University of WashingtonLead Sponsor
1,812 Previous Clinical Trials
1,913,670 Total Patients Enrolled
24 Trials studying Multiple Sclerosis
3,535 Patients Enrolled for Multiple Sclerosis
Charles H Bombardier, PhDPrincipal InvestigatorUniversity of Washington
1 Previous Clinical Trials
15 Total Patients Enrolled
~10 spots leftby Nov 2025